New malaria vaccine shows promise in first human trial
NCT ID NCT06652737
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new malaria vaccine made from genetically weakened parasites that stop growing in the liver and cannot cause blood-stage infection. The goal was to see if it is safe and triggers a strong immune response. The trial involved 75 healthy adults and children in Burkina Faso who are regularly exposed to malaria.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Groupe de Recherche Action en Santé (GRAS) / Unité de Recherche Clinique de Sabou
Ouagadougou, 06, Burkina Faso
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental malaria vaccine aims to block parasite growth
- New malaria drug interaction study launches in healthy volunteers
- New malaria shots could replace daily pills
- New malaria antibody enters first human safety tests
- Breastfeeding moms with malaria: do drugs reach baby?
- New malaria pill shows promise in early trial